scholarly journals Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer

2009 ◽  
Vol 22 (9) ◽  
pp. 1151-1159 ◽  
Author(s):  
Sophia K Apple ◽  
Alarice C Lowe ◽  
P Nagesh Rao ◽  
I Peter Shintaku ◽  
Neda A Moatamed
Keyword(s):  
Breast Cancer ◽  
In Situ Hybridization ◽  
Core Needle Biopsy ◽  
Primary Breast Cancer ◽  
Needle Biopsy ◽  
Fluorescent In Situ Hybridization ◽  
Excisional Biopsy ◽  
Core Needle ◽  
Her 2

Lobular In-Situ Neoplasia on Breast Core Needle Biopsy: Imaging Indication and Pathologic Extent Can Identify Which Patients Require Excisional Biopsy

2011 ◽  
Vol 19 (3) ◽  
pp. 914-921 ◽  
Author(s):  
Mara H. Rendi ◽  
Suzanne M. Dintzis ◽  
Constance D. Lehman ◽  
Kristine E. Calhoun ◽  
Kimberly H. Allison
Keyword(s):  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Excisional Biopsy ◽  
Core Needle

The reliability of HER2-status determination from core-needle-biopsies and surgical specimens: A comparison of two established test methods (IHC, CISH)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22141-e22141
Author(s):  
V. Wolf ◽  
R. Groβe ◽  
J. Erggelet ◽  
H. J. Holzhausen ◽  
S. Hauptmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
In Situ Hybridisation ◽  
Test Method ◽  
Her2 Status ◽  
Surgical Specimen ◽  
Core Needle ◽  
Significant Difference ◽  
Her 2

e22141 Background: A milestone of breast-cancer therapy was the discovery of HER-2 entailing special targeted therapy with improved prognosis. The HER-2-status is routinely assessed through immunohistochemistry (IHC; HercepTest) showing protein over-expression and is double-checked with in-situ-hybridisation (ISH) demonstrating gene amplification in equivocal cases. It is questioned whether these methods achieve identical results in core-needle-biopsies and in excisional tumor specimens. Methods: We performed a retrospective comparative study in order to address these questions. From 01/03–06/08 we collected the HercepTest results from both core-needle-biopsy and surgical specimen of 109 breast cancer patients in our institute and compared these to newly evaluated chromogenic ISH (CISH) results for both specimen types in order to assess the reliability of HER-2- diagnosis of both methodological approaches and of specimen type. Results: We found no significant difference in the HER- 2-status determined from either needle-biopsies or surgical specimens irrespective of the test used. For the overall comparison (218 specimens) of HercepTest and CISH we found only slight, non-significant deviations. Four cases were CISH-negative in spite of HercepTest scoring of 3+. Vice versa, five out of the total of 38 (17.4%) CISH-positives did not correspond to the HercepTest results of 0 or 1+. Conclusions: Though not significant, there is some inconsistency in the HER-2-determination depending on the test-method, leaving these cases equivocal. In accordance with the literature, we therefore recommend to at least double-check samples with 2+ in the HercepTest as it is the current standard. Our data support the use of core-needle-biopsy as a reliable tissue sample for HER-2-diagnosis. [Table: see text]

Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer

2004 ◽  
Vol 116 (1-2) ◽  
pp. 26-31 ◽  
Author(s):  
Susanne Taucher ◽  
Margaretha Rudas ◽  
Robert M. Mader ◽  
Michael Gnant ◽  
Peter Dubsky ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Core Needle Biopsy ◽  
Primary Breast Cancer ◽  
Needle Biopsy ◽  
Prognostic Markers ◽  
Core Needle
Sign in / Sign up

Export Citation Format

Share Document